Type II Diabetes with High Vascular Risk (1218.22 “Carmelina”)

The purpose of the CARMELINA Study is to look at the impact of an investigational drug called linagliptin on the long-term occurrence of selected complications of cardiovascular disease (e.g. stroke or heart attack), as compared to placebo, in people with type 2 diabetes mellitus receiving standard of care.

Register Today!

Trial Information

Start DateJanuary 2014
End DateAugust 2018
Trial Duration2 years
Number of Visits18
Lead CRCJessica Richer

For additional information
on this trial contact: